C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial

Temesgen, Z; Kelley, CF; Cerasoli, F; Kilcoyne, A; Chappell, D; Durrant, C; Ahmed, O; Chappell, G; Catterson, V; Polk, C; Badley, A; Marconi, VC

Temesgen, Z (通讯作者)，Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA.

THORAX, 2023; 78 (6): 606

Abstract

Objective COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the p......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索